Medicenna Therapeutics Corp has seen a slight uptick in its stock price this week, driven by recent financing activities.
This week, Medicenna Therapeutics Corp (MDNA.TO) experienced a modest increase in its stock price, closing at C$0.41. The stock rose by 3.75% over the week, reflecting investor sentiment following the company's recent public offering announcement. Medicenna's activities in the health care sector, particularly in oncology, remain a focal point for investors as the company seeks to advance its therapeutic programs.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$37.84M
52W high
$1.97
52W low
$0.34
1W change
+3.75%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 671.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+671.1% Upside
Current Price
C$0.41
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
57.6%
Annualized
90-Day Vol
70.7%
Annualized
Trend (90d)
-24.6%
Annualized drift
90d Mean
C$0.38
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.40 | C$0.33 – C$0.49 |
| 60 trading days | C$0.39 | C$0.30 – C$0.52 |
| 90 trading days | C$0.38 | C$0.27 – C$0.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the implications of Medicenna's recent public offering and its ongoing clinical developments as potential catalysts for future performance.
Medicenna Raises CDN$4.44 Million Through Public Offering
The recent public offering at CDN$0.50 per unit aims to bolster Medicenna's financial resources as it develops its therapeutic programs.
Bull case
The successful closing of the public offering raised approximately CDN$4.44 million, showing that investors are confident in Medicenna's lead programs. This funding could improve the company's financial stability and support future growth.
Bear case
Despite the recent uptick in stock price, Medicenna's year-to-date performance is concerning, with a decline of 58.50%. The company continues to operate at a loss, which may deter some investors.
Price Action Overview
Advertisement
Medicenna Therapeutics Corp closed at C$0.41, reflecting no change in price for the day. Over the past week, the stock appreciated by 3.75%, and in the last month, it has gained 18.57%. However, its year-to-date performance shows a significant decline of 58.50%, indicating volatility and challenges faced by the company.
Recent Company News
This week, Medicenna announced the successful closing of a public offering of units priced at CDN$0.50 each, raising approximately CDN$4.44 million. This funding is earmarked to support the company's lead programs, which include their innovative anti-PD-1 x IL-2 bifunctional superkine, MDNA113. The company also finalized the terms of the offering and filed a prospectus supplement, ensuring transparency in its financial dealings.
Technical Picture
From a technical standpoint, Medicenna's stock is currently trading above its 50-day moving average of C$0.39, indicating a short-term bullish trend. However, it remains significantly below its 200-day moving average of C$0.75, suggesting long-term challenges. The stock has a beta of 1.89, indicating higher volatility compared to the broader market. The 52-week range is between C$0.34 and C$1.97, with the current price at approximately 5% of this range. Recent trading volume was 26,254 shares, which is about 55% of the 20-day average volume of 46,923 shares.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
